1 Moehler M, Al-Batran SE, Andus T, et al. S3-Leitlinie «Magenkarzinom» Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. Z Gastroenterol. 2011;49:461–531.
2 Hölscher AH, Stahl M, Messmann H, et al. New S3 guideline for esophageal cancer: important aspects. Chirurg. 2016;87(10):865–72.
3 Mönig SP, Schiffmann LM. Resection of advanced esophagogastric adenocarcinoma: extended indications. Chirurg. 2016;87(5):398–405.
4 Lordick F. Resect or not resect in metastatic gastric cancer: that is the question. Gastric Cancer. 2012;15(3):229–31.
5 Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Lonati V, et al. Hepatic resection for gastric cancer liver metastases: A systematic review and meta-analysis. Journal of surgical oncology. 2015;111(8):1021–7.
6 Martella L, Bertozzi S, Londero AP, Steffan A, De Paoli P, Bertola G. Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine. 2015;94(31):e1113.
7 Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.